Phase I Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer With Homologous Recombination Deficiency (PreCISeRT)
Summary
The purpose of this phase I trial is to evaluate the safety and efficacy of the combination of radiation therapy (RT) and Gemcitabine and Cisplatin in patients with metastatic pancreatic cancer that has spread to the liver.
General Information
NCT#: NCT05182112
Study ID: 21-443
Trial Phase: Phase I
Trial Sponsor: Memorial Sloan Kettering
Therapies Used in This Trial: Gemcitabine, Cisplatin